CORRECTION OF RESISTANT ARTERIAL HYPERTENSION IN PATIENTS WITH CHRONICKIDNEYDISEASE STAGE I–III
Abstract
Aim. The aim was to investigate the use of the I1–imidazoline receptor agonist moxonidine as an ‘add–on’ agent and determine its effect on heart rate variability in patients with CKD st. I–III and resistant hypertension.
Methods. We investigated the safety and efficacy of moxonidine (200–600 mg) in a group of 35patients with CKD st. I–III whose had prior treatment with three or more antihypertensive medications, although without adequate control [systolic blood pressure (SBP) 145–165 mm Hg and/or diastolic BP (DBP) 95–100 mm Hg]. BP was measured according to internationally accepted guidelines before and after 3 month of treatment with moxonidine used as an ‘add–on’ agent in the patients with CKD st. I–III and resistant hypertension. Age ofpatients was 53±5,8 years. Glomerular filtration rate (GFR) before treatment was 68,7±23,0 mL/min/1,73m 2. Before and 3 months after treatment, we determined improvement in the time–frequency analysis of heart rate variability.
Results. Following treatment with moxonidine, the SBP significant fell from 153.6±8.1 to 130.7±4.6 mmHg (P< 0.001). The DBP also showed a significant reduction from 96.7±2,4 to 80.9±2,6 mmHg (P< 0.001). Reduction
of SBP pressure was 22.9±7.9 mm Hg and reduction of DBP was 15.9±3.1 mm Hg. 29patients (83%) achieved the goal blood pressure – 130/80 mm Hg and less. 5 patients (14%) were not achieve goal blood pressure, but blood pressure lowered <140/90 mm Hg. In 1 patient (3%) blood pressure decreased from 160/100 mm Hg to 145/90 mm Hg. The majority of patients (28 – 80%)
Downloads
References
Burden of resistant hypertension in hypertensive patients with non–dialysis chronic kidney disease / L. De Nicola, S. Borrelli, F. B. Gabbai [et al.] // Kidney Blood Press. Res. – 2011. – Vol. 34. – P. 58–67.
Fagard R. H. Resistant hypertension / R. H. Fagard // Heart. – 2012. – Vol. 98. – P. 254–261. – Режим доступу : http://heart.bmj.eom/content/98/3/254. full.pdf.
Park J. Cardiovascular risk in chronic kidney disease: role of the sympathetic nervous system / J. Park // Cardiology Research and Practice. – 2012. – Vol. –
– 8 p.
Persell S. D. Prevalence of resistant hypertension in the United States, 2003–2008 / S. D. Persell // Hypertension. – 2011. – Vol. 57. – P. 1076–1080.
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research / D. A. Calhoun, D. Jones, S. Textor [et al.] // Hypertension. – 2008. – Vol. 51. – P. 1403–1419.
Resistant hypertension revisited : a comparison of two university–based cohorts / J. P. Garg, W. J. Elliott, A. Folker [et al.] // Am. J. Hypertens. – 2005. – Vol. 18. – P. 619–626.
Standards of measurements, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (Membership of the Task Force listed in the Appendix) // Europ. Heart J. – 1996. – Vol. 17. – P. 354–381.
Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment / E.L. Penne, J. Neumann, I.H. Klein [et al.] // J. Nephrol. – 2009. – Vol. 22(2). – P. 208215.
Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment / J. Neumann, G. Ligtenberg, I. I. Klein [et al.] // Kidney Int. – 2004 – Vol. 65(5) – P. 1568–1576.
